Quantcast
ZME Science
  • CoronavirusNEW
  • News
  • Environment
    • Climate
    • Animals
    • Renewable Energy
    • Eco tips
    • Environmental Issues
    • Green Living
  • Health
    • Alternative Medicine
    • Anatomy
    • Diseases
    • Genetics
    • Mind & Brain
    • Nutrition
  • Future
  • Space
  • Feature
    • Feature Post
    • Art
    • Great Pics
    • Design
    • Fossil Friday
    • AstroPicture
    • GeoPicture
    • Did you know?
    • Offbeat
  • More
    • About
    • The Team
    • Advertise
    • Contribute
    • Our stance on climate change
    • Privacy Policy
    • Contact
No Result
View All Result
ZME Science

No Result
View All Result
ZME Science
No Result
View All Result
Home Health & Medicine

New vaccine is incredibly efficient at preventing typhoid

Antibiotic-resistant typhoid is spreading in some parts of the world so this news comes in the nick of time.

Melvin Sanicas by Melvin Sanicas
December 5, 2019
in Health & Medicine, News, Science

Caused by the bacterium Salmonella Typhi, typhoid is a major cause of fever in children in low- and middle-income countries and is responsible for nearly 11 million cases and more than 116,000 deaths a year worldwide.

It is usually spread through contaminated food or water. Once Salmonella Typhi bacteria are eaten or drunk, they multiply and spread into the bloodstream. Symptoms include prolonged high fever, fatigue, headache, nausea, abdominal pain, and constipation or diarrhoea. Some patients may have a rash. Severe cases may lead to serious complications or even death. Salmonella Typhi lives only in humans.

In 2018, the World Health Organization (WHO) recommended the introduction of typhoid conjugate vaccine (TCV) for infants and children over six months of age in typhoid-endemic countries, and added it to its list of pre-qualified vaccines.

Prior to TCV, two vaccines have been used for many years to protect people from typhoid fever, an injectable vaccine based on the purified antigen for people aged over 2 years and a live attenuated oral vaccine in capsule formulation for people aged over 5 years. These vaccines do not provide long-lasting immunity and are not approved for children younger than 2 years old.

Although TCV has been shown to protect against the disease in studies involving healthy volunteers in the UK, no efficacy studies in endemic populations had been completed. Now, the Typhoid Vaccine Acceleration Consortium (TyVAC), which includes researchers from the University of Oxford, the University of Maryland School of Medicine, and PATH has completed a large field study in Nepal and published the interim analysis in the New England Journal of Medicine.

Get more science news like this...

Join the ZME newsletter for amazing science news, features, and exclusive scoops. More than 40,000 subscribers can't be wrong.

   

The study involved 20,000 children aged 9 months to 16 years of age, who were randomly given one of two vaccines: half received TCV and half received the Group A meningococcal (MenA) vaccine – the latter acted as the control group.

Blood tests showed that typhoid occurred in 7 participants who received TCV and 38 receiving Men A vaccine. The researchers noted that these were preliminary results, and that the study will continue to follow-up the participants for two years.

Dr. Andrew Pollard, Professor of Paediatric Infection and Immunity at Oxford University’s Department of Paediatrics, said: “This is the first study to show that a single dose of TCV is safe, immunogenic, and effective, which provides clear evidence that vaccination will help efforts to control this serious disease and is a strong endorsement of the WHO policy for vaccine implementation.”

“The efficacy of these results in an endemic population adds to a growing body of evidence supporting the use of TCV to reduce disease and save lives in populations that lack clean water and improved sanitation,” said Dr. Kathleen Neuzil, MD, MPH director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine and director of TyVAC.

These results show the vaccine has the potential to significantly reduce the burden of typhoid in high-risk populations. This is especially timely with the recent spread of extensively drug-resistant typhoid, which threatens child health in affected regions.

Pakistan’s current typhoid outbreak is the first-ever reported outbreak of ceftriaxone-resistant typhoid and represents an alarming trend in the spread of drug-resistant typhoid. Not only is the strain resistant to ceftriaxone, the standard treatment in many parts of the world, but it is also resistant to most antibiotics commonly used for typhoid, making it increasingly challenging and costly to treat.

TCVs have the potential to overcome many of the challenges that impeded uptake of earlier vaccines, including longer-lasting protection, fewer doses, and suitability for children under two years of age, allowing for inclusion in routine childhood immunization programs.

Tags: global healthPublic Healthsalmonellatyphoid fevervaccine
Melvin Sanicas

Melvin Sanicas

Melvin is a curious lifelong learner. He studied biology, medicine, health economics, infectious diseases, clinical development, and public policy. He writes about global health, vaccines, outbreaks, and pathogens.

Follow ZME on social media

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
  • Coronavirus
  • News
  • Environment
  • Health
  • Future
  • Space
  • Feature
  • More

© 2007-2019 ZME Science - Not exactly rocket science. All Rights Reserved.

No Result
View All Result
  • Coronavirus
  • News
  • Environment
    • Climate
    • Animals
    • Renewable Energy
    • Eco tips
    • Environmental Issues
    • Green Living
  • Health
    • Alternative Medicine
    • Anatomy
    • Diseases
    • Genetics
    • Mind & Brain
    • Nutrition
  • Future
  • Space
  • Feature
    • Feature Post
    • Art
    • Great Pics
    • Design
    • Fossil Friday
    • AstroPicture
    • GeoPicture
    • Did you know?
    • Offbeat
  • More
    • About
    • The Team
    • Advertise
    • Contribute
    • Our stance on climate change
    • Privacy Policy
    • Contact

© 2007-2019 ZME Science - Not exactly rocket science. All Rights Reserved.